The use of anti-4-1BB/anti-OX-40 T-cell agonist antibodies rescued effects of MEK inhibition on T-cells via redirection of MAPK signalling towards increased downstream activation of p38/JNK and PI3K/AKT pathways, resulting in augmented anti-tumour effects which significantly prolonged survival in immunocompetent mouse models of TNBC [178]. Here, TNFRSF9 is linked to neoplasm.